Nav: Home

New uses for existing antiviral drugs

April 25, 2018

Zika virus. Ebola virus. Influenza. SARS and MERS corona viruses. Existing and emerging viral diseases are an increasing problem, particularly in developing countries. The World Health Organization has called for better control of viral diseases, but developing drugs for this purpose can be challenging.

Now, a multinational team of scientists and clinicians led by Denis Kainov from the Norwegian University of Science and Technology (NTNU) has reviewed all approved, investigational and experimental antiviral agents that have been shown to be safe in humans to search for new uses for these substances against existing and emerging viruses The results have just been published in Antiviral Research.

Antiviral drugs and vaccines are the most powerful tools to combat viral diseases. Most drugs and vaccines, however, selectively target a single virus, thereby providing a "one drug-one bug" solution, the researchers say.

In contrast, broad-spectrum antivirals (BSAs) can cover multiple viruses and genotypes and reduce the likelihood of development of resistance.

Therefore, some BSAs can be used for the rapid management of new or drug-resistant viral strains, for a first-line treatment or for prophylaxis of acute virus infections, as well as for viral co-infections, which can reduce the complexity of treatment.

With this in mind, the team identified 59 compounds already shown to be safe in humans that targeted at least three viral diseases. The researchers then tested 55 of these compounds on eight different viruses, and found that seven showed new effects against HIV-1, Zika virus and Rift Valley Fever.

"Re-purposing these therapeutics from one viral disease to another could save resources and time needed for development of novel drugs," Kainov said.

The researchers say that their results show existing safe-in-human BSAs could be used on other viral infections. The goal is to create broad-spectrum antiviral drugs, much like the broad-spectrum antibacterial drugs that are currently available.

"Effective treatment with broad-spectrum antivirals may shortly become available, pending the results of further pre-clinical studies and clinical trials. The most effective and tolerable compounds will expand the available therapeutics for the treatment of viral diseases," said Aleksandr Ianevsky, the first author of the study and a PhD student at NTNU.

"We hope that not only broad-spectrum antibiotics but also broad-spectrum antivirals will be available in a future," said Magnar Bjørås, a professor at NTNU's Department of Molecular Medicine. "These drugs could be used as first-line therapeutics to combat emerging and re-emerging viral threats that have a global impact, improving preparedness and the protection of the general population from viral epidemics and pandemics."
-end-
Reference: Aleksandr Ianevski, Eva Zusinaite, Suvi Kuivanen et al. Novel activities of safe-in-human broad-spectrum antiviral agents, Antiviral Research, Online 23 April 2018. https://doi.org/10.1016/j.antiviral.2018.04.016

Norwegian University of Science and Technology

Related Zika Virus Articles:

Unravelling mother to baby transmission of Zika virus
Researchers have discovered that when a pregnant mother is infected by Zika virus, it can remain in the placenta for months, causing damage that can be dangerous to the fetus.
Consequences of Zika virus attack on glial cells
Few studies have identified the effects of zika virus infection on astrocytes, as well as their association with developmental alterations, including brain malformations and microcephaly.
Breakthrough in Zika virus vaccine
Researchers from the University of Adelaide have made significant advances in developing a novel vaccine against Zika virus, which could potentially lead to global elimination of the disease.
How the Zika virus can spread
The spread of infectious diseases such as Zika depends on many different factors.
Prior Zika virus or dengue virus infection does not affect secondary infections in monkeys
Previous infection with either Zika virus or dengue virus has no apparent effect on the clinical course of subsequent infection with the other virus, according to a study published August 1 in the open-access journal PLOS Pathogens by David O'Connor of the University of Wisconsin-Madison, and colleagues.
Early dengue virus infection could "defuse" zika virus
The Zika virus outbreak in Latin America has affected over 60 million people up to now.
Long-term consequences of Zika virus infection
Mice exposed to the Zika virus during later stages of gestation present behaviors reminiscent of attention-deficit/hyperactivity disorder, according to a study of genetically diverse animals.
Protection from Zika virus may lie in a protein derived from mosquitoes
By targeting a protein found in the saliva of mosquitoes that transmit Zika virus, Yale investigators reduced Zika infection in mice.
Dengue virus infection may cause severe outcomes following Zika virus infection during pregnancy
This study is the first to report a possible mechanism for the enhancement of Zika virus progression during pregnancy in an animal model.
Dengue virus immunity may protect children from Zika symptoms
Previous infection with dengue virus may protect children from symptomatic Zika, according to a study published Jan.
More Zika Virus News and Zika Virus Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Debbie Millman: Designing Our Lives
From prehistoric cave art to today's social media feeds, to design is to be human. This hour, designer Debbie Millman guides us through a world made and remade–and helps us design our own paths.
Now Playing: Science for the People

#574 State of the Heart
This week we focus on heart disease, heart failure, what blood pressure is and why it's bad when it's high. Host Rachelle Saunders talks with physician, clinical researcher, and writer Haider Warraich about his book "State of the Heart: Exploring the History, Science, and Future of Cardiac Disease" and the ails of our hearts.
Now Playing: Radiolab

Insomnia Line
Coronasomnia is a not-so-surprising side-effect of the global pandemic. More and more of us are having trouble falling asleep. We wanted to find a way to get inside that nighttime world, to see why people are awake and what they are thinking about. So what'd Radiolab decide to do?  Open up the phone lines and talk to you. We created an insomnia hotline and on this week's experimental episode, we stayed up all night, taking hundreds of calls, spilling secrets, and at long last, watching the sunrise peek through.   This episode was produced by Lulu Miller with Rachael Cusick, Tracie Hunte, Tobin Low, Sarah Qari, Molly Webster, Pat Walters, Shima Oliaee, and Jonny Moens. Want more Radiolab in your life? Sign up for our newsletter! We share our latest favorites: articles, tv shows, funny Youtube videos, chocolate chip cookie recipes, and more. Support Radiolab by becoming a member today at Radiolab.org/donate.